🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

At #VitafoodsEurope2025, meet with #AptarPharma at Booth 3F205 to learn how we can add to your #nutritionalsupplement product range. Explore our #oralliquiddispensing products, including our Micro+ Futurity, a fully recyclable monomaterial Airless+ pump. See you there!

Developing #GLP1 drugs? Patient #self-injection with #autoinjectors or pens is key for type 2 diabetes & obesity treatment. Learn how #AptarPharma's Rigid Needle Shields, Pre-Filled Syringe plungers & Services can boost your drug development. ow.ly/OFGv50VAEUH

Congratulations to Kimberly Chainey, Aptar’s EVP, CLO and Corporate Secretary, who was recognized last night with a "Legends in the Law" Award by The Burton Awards at the Library of Congress in Washington D.C. Read more at ow.ly/fAXL50VVXH1 #Aptar #BeYouBeAptar

Attending #VitafoodsEurope2025? Discover #AptarPharma's Micro+ Futurity, a fully recyclable monomaterial Airless+ pump designed for convenient application of viscous formulations. Also, learn more about our oral liquid dispensing products. Stop by Booth 3F205 & meet our team!

Aptar Digital Health announces licensing agreement with AstraZeneca to develop AI-powered screening algorithms; agreement aims to enhance patient outcomes via early detection of hard-to-detect diseases like #CKD. ow.ly/Aqut50VWYl9 #AIInnovation #DigitalHealth

Aptar Digital Health announces licensing agreement with AstraZeneca to develop AI-powered screening algorithms; agreement aims to enhance patient outcomes via early detection of hard-to-detect diseases like #CKD. ow.ly/GetB50VX0oH #AIInnovation #DigitalHealth

Aptar Pharma's in-house #elastomermanufacturing for valve gaskets enhances your #supplychain security & ensures full change control. Our commitment to quality & reliability supports the development of your next-generation #pMDI. ow.ly/9V5550VXz9k #ZEN30Futurity

Read Aptar Pharma's latest article “Spotlight on Emissions Reductions for a Lower CO₂ Footprint in Pharmaceutical Packaging,” to find out how we are advancing responsible innovation in inhalation drug delivery. ow.ly/Vq8v50VXzOw

Proud to share that our President & CEO, Stephan Tanda, appeared on Bloomberg Television's Open Interest program to discuss how our strategic "in region for region" manufacturing positions us for success amid global trade uncertainties. Watch the video: ow.ly/SVs250VZEQ1

Our latest article, “The Power of Pulmonary: Advances in Inhaled Drug Delivery Expand Respiratory Treatment Options” explores how advanced technologies are expanding the therapeutic potential of inhaled #drugdelivery, beyond traditional #respiratorycare. ow.ly/3bqR50VXCyR

We're pleased to share our 2024 Corporate Sustainability Report, Progress Takes Shape, which details our renewable energy adoption, waste reduction, product circularity and community engagement. View the report: ow.ly/lzWo50W1ePM #Aptar #Sustainability

Our #Unidose system began as a breakthrough in single-dose delivery & has become a global #nasaldelivery platform. From routine to emergency use, #AptarPharma's single-dose #nasalspray system meets the needs of adult & pediatric patients. ow.ly/hcAm50W2qkw #FDAapproved

As we enter #Pride Month—a time to celebrate the vibrant history and contributions of the LGBTQIA+ community and its allies. We will continue to build a workplace where authenticity is embraced and everyone can bring their whole selves to work. ow.ly/rXOz50VZy3h

Join #AptarPharma & Noble for a webinar on GLP-1 Drug Development on June 19, 2025. Find out how we can support your GLP-1 drug development journey, from formulation to patient. ​ ​Register today: ow.ly/jE9l50W47T3 #Injectables #Drugdevelopment #PatientExperience #GLP1

Join #AptarPharma at #PDD2025 Istanbul, June 11–13. Stop by our table to discover our latest developments in inhalation #drugdelivery. Our 3 speakers will present on biologics & amorphous matrices, advanced formulations & sustainable #lowGWP inhalation technologies. See you then!

Changes in #injectable #drugpackaging as USP <382> shifts focus to full-system testing is a major leap for pharma. In #AptarPharma's latest published Q&A, “USP <382>: Key Questions to Understand the Impact”, we explain what this means for developers. ow.ly/BsJF50W6USx

Navigate #regulatory complexity with #AptarPharma. #Nanopharm's #SmartTrack™ modeling platform helps you demonstrate the #bioequivalence of inhaled products to reference drugs without a comparative clinical endpoint (CCEP) study. ow.ly/L4PX50W4gVG #LowGWP #pMDI

Just one week to go! Join #AptarPharma & #Noble for our exclusive webinar on #GLP1 #drugdevelopment. 🔍Learn about our integrated offer & discover how we can help accelerate your time to market & enhance patient engagement. 👉 Register now to secure your spot!

Trusted by thousands of users every day for its precision and reliability, #AptarPharma's single-dose #Unidose #nasalspray system ensures effective administration, supporting patients worldwide for both routine & emergency use. ow.ly/Rsh050W4REt. #NasalDelivery

#AptarPharma will be at #ISAM2025 in Washington, D.C. from June 22–25, 2025. Join us on Sunday, June 22 from 9 - noon for the #IntranasalDelivery of Aerosolized Vaccines workshop and hear from our experts, Julie Suman and Goncalo Farias, on the future of vaccine delivery.